ADVA
12.9.2019 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has been selected as the strategic technology partner of Sify Technologies Limited. Sify, the largest ICT service provider in India, is deploying the ADVA FSP 150 as the foundation of its new managed Ethernet service offering. The intelligent, multi-layer demarcation and aggregation technology will enable Sify to deliver secure, highly reliable end-to-end Ethernet services, leveraging its nationwide MPLS core network. The offering completes Sify’s ICT solution suite and empowers its end users to streamline operations, cut costs and rapidly seize new business opportunities. In addition to providing intelligent managed enterprise services, Sify will use the ADVA technology to extend its wholesale service footprint, giving more international carriers access to the Indian subcontinent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005040/en/
“Our new managed Ethernet offering fills the final gap in our portfolio. With ADVA as our technology partner, we can roll out high-capacity Layer 2 services with total flexibility and bring intelligence and automation to the edge of our enterprise network,” said Harsha Ram, VP, telecom services, Sify. ”The ADVA FSP 150 delivers new levels of agility for service innovation. It empowers us to provide the ideal solution for the budget, strategy and technical needs of each and every customer. What’s more, with ADVA’s technology, we can put IP traffic control at the end user’s fingertips. With incredible speed and efficiency, customers can take charge of their services, managing IP addresses and altering IP routing without restriction.”
With more than 10,000 enterprise customers across the Indian subcontinent, Sify has seen an enormous increase in data demand. The ADVA FSP 150 is the ultimate response. Deployed at the customer premises, the ADVA FSP 150 demarcation solution delivers MEF-certified CE 2.0 services and provides several key advantages. It’s highly interoperable, enabling seamless integration with Sify’s existing network management system. With its comprehensive set of service assurance functions, the solution offers full visibility of service quality – an essential tool for effective SLA management. The device also provides the flexibility to quickly transition from 1Gbit/s to 10Gbit/s Ethernet services without requiring extra space and power consumption.
“Our FSP 150 technology has always been at the forefront of Ethernet access innovation. Now we’re using all of our experience as a global leader with an enormous installed base to bring scalable, SLA-assured business and cloud access to Sify’s customers. With our multi-technology platform, Sify will be able to reduce costs and significantly simplify operations,” commented Sivakumar Krishna Iyer, director, global business development, ADVA. “Our FSP 150 provides comprehensive assurance, delivering unparalleled support for SLA management. It also effortlessly expands from 1GbE to 10GbE. What’s more, our solution offers zero-touch provisioning as standard so it can easily be installed and connected by customers with no risk of error. This makes it the ideal technology to enable major operators like Sify to rollout tomorrow’s business connectivity on an enormous scale.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com
.
About Sify Techologies
Sify is the largest ICT service provider, system integrator and all-in-one network solutions company on the Indian subcontinent. We’ve also expanded to the United States, with headquarters in the heart of California’s Silicon Valley. Over 10,000 businesses have become Sify customers. We also partner with other major network operators to deliver global network solutions. Our customers can access Sify services via India’s largest MPLS network. Among the very few enterprise class players in India, Sify, today has presence in more than 1,600 cities in India and in North America, the United Kingdom and Singapore. www.sifytechnologies.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
